Amphastar Pharmaceuticals (AMPH) Debt to Equity (2013 - 2026)

Amphastar Pharmaceuticals' Debt to Equity history runs 14 years deep, the most recent figure standing at $0.79 for Q1 2026.

• In Q1 2026, Debt to Equity fell 1.67% year-over-year to $0.79; the TTM figure through Mar 2026 stood at $0.79 (down 1.67% YoY), while the FY2025 annual figure was $0.77, down 5.85% from the prior year.
• Debt to Equity was $0.79 for Q1 2026 at Amphastar Pharmaceuticals, up from $0.77 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $1.07 in Q3 2023 to a low of $0.14 in Q1 2023.
• Historically, Debt to Equity has averaged $0.64 across 5 years, with a median of $0.8 in 2025.
• The sharpest annual moves came in 2023 and 2024: Debt to Equity jumped 616.19% in 2023, then decreased 23.58% in 2024.
• A 5-year view of Debt to Equity shows it stood at $0.14 in 2022, then surged by 542.83% to $0.92 in 2023, then retreated by 10.93% to $0.82 in 2024, then decreased by 5.85% to $0.77 in 2025, then climbed by 2.17% to $0.79 in 2026.
• The last three Debt to Equity figures came in at $0.79 (Q1 2026), $0.77 (Q4 2025), and $0.78 (Q3 2025), per Business Quant data.